Methods for detecting ALK-positive NSCLC have evolved from fluorescence in situ hybridization and immunohistochemistry to next-generation DNA sequencing, targeted RNA sequencing, and whole transcriptome sequencing. This evidence concerns the gene ALK and non-small cell lung carcinoma.